Onconova Therapeutics Inc (NASDAQ:ONTX)’s share price traded down 5.6% during mid-day trading on Tuesday following a dissappointing earnings announcement, Analyst Ratings.Netreports. The stock traded as low as $5.00 and last traded at $5.02, with a volume of 405,465 shares changing hands. The stock had previously closed at $5.32. Onconova Therapeutics Inc (NASDAQ:ONTX), weekly performance is -10.31%. On last trading day company shares ended up $4.87. Analysts mean target price for the company is $11.50. Onconova Therapeutics Inc (NASDAQ:ONTX), distance from 50-day simple moving average (SMA50) is -3.13%.
Celgene Corporation (NASDAQ:CELG)’s shares fell 1.47% to $88.86 in the last trading session. Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (CELG) on June 14 announced that a retrospective analysis of MM-003, the Company’s phase III study of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory multiple myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination, were presented at the 19th European Hematology Association annual congress. Pomalidomide is marketed as POMALYST® in the United States and IMNOVID® in the European Union. Celgene Corporation (NASDAQ:CELG), fell 3.53% in last trading session and ended the day on $85.72. CELG, Gross Margin is 94.90% and its return on assets is 10.40%. Celgene Corporation (NASDAQ:CELG), quarterly performance is 23.20%.
The FDA approved Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), Beleodaq for the treatment of patients suffering from relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). Beleodaq was approved well ahead of the target date of Aug 9 under the FDA’s accelerated approval program. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), shares moved down 4.29% in last trading session and was closed at $8.26, while trading in range of $8.24 – 8.62. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), year to date (YTD) performance is -6.67%.
Analysts at Cantor Fitzgerald started coverage on shares of Array Biopharma Inc (NASDAQ:ARRY), in a research report issued to clients and investors on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock. Array Biopharma Inc (NASDAQ:ARRY), ended the last trading day at $4.19. Company weekly volatility is calculated as 6.04% and price to cash ratio as 4.80. Array Biopharma Inc (NASDAQ:ARRY), showed a negative weekly performance of 8.11%.
Leave a Reply